Clinical trial

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

NCT04032847

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-07-08

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2019-07-08Date precision: day

Registry last updated2025-03-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Non Small Cell Lung Cancerunresolved

Interventions

ATL001BIOLOGICAL

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Achilles Therapeutics UK Limitedlead sponsor

Mapped research locations

MadridSpain2 LondonUnited Kingdom2 ManchesterUnited Kingdom2 New YorkNew York, United States1 TampaFlorida, United States1 New HavenConnecticut, United States1 ValenciaSpain1 DresdenGermany1 EssenGermany1 BirminghamUnited Kingdom1 CambridgeUnited Kingdom1 Pierre-BéniteFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04032847 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.